stockrowBridgeBio Pharma, Inc.
BBIO Healthcare Biotechnology
BridgeBio Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $502.1 million, up 126.3% from fiscal 2024.
- Revenue
- +192.6%
- EPS
- +55.8%
- Free cash flow
- +60.5%
- Total debt
- +4.21%
Quarter to September 2026, against a year earlier
Follow BBIO
Alert me
BridgeBio Pharma, Inc. (BBIO) Return on assets
BridgeBio Pharma, Inc.'s return on assets over the twelve months to 30 September 2026 was −37.5%, up 40.7 percentage points from fiscal 2025 (−78.1%). Over the past ten years it has ranged from −110.0% (fiscal 2023) to −10.9% (fiscal 2017); the current reading is higher than 22% of that period. That is above the Biotechnology industry median of −45.6% and below the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −78.1% | (5.03) |
| FY2024 | −73.1% | 36.89 |
| FY2023 | −110.0% | (51.17) |
| FY2022 | −58.8% | 6.72 |
| FY2021 | −65.6% | 1.66 |
| FY2020 | −67.2% | (19.68) |
| FY2019 | −47.5% | 8.71 |
| FY2018 | −56.2% | (45.38) |
| FY2017 | −10.9% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| ASND Ascendis Pharma A/S compare | 44.3% |
| EXEL Exelixis, Inc. compare | 33.2% |
| HALO Halozyme Therapeutics, Inc. compare | 17.1% |
| TECH Bio-Techne Corp compare | 7.07% |
| JAZZ Jazz Pharmaceuticals PLC compare | 1.76% |
| BMRN BioMarin Pharmaceutical Inc. compare | −0.20% |
| KYMR Kymera Therapeutics, Inc. compare | −24.4% |
| BBIO BridgeBio Pharma, Inc. | −37.5% |
| SMMT Summit Therapeutics PLC compare | −159.1% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on BBIO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement